Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: BIOLOGICAL: HER-2 pulsed DC1|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Paclitaxel|PROCEDURE: Resection surgery
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: ImmunoRestoration